Clopidogrel/levamlodipine

Drug Profile

Clopidogrel/levamlodipine

Alternative Names: Levamlodipine/clopidogrel; S-amlodipine besylate/clopidogrel bisulphate tablet - Emcure Pharmaceuticals

Latest Information Update: 08 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Emcure Pharmaceuticals
  • Class Antihypertensives; Antiplatelets; Dihydropyridines; Nicotinic-acids; Pyridines; Small molecules; Thiophenes
  • Mechanism of Action Calcium channel antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cardiovascular disorders; Hypertension; Thrombosis

Most Recent Events

  • 01 Sep 2015 No recent reports on development identified - Phase-III for Hypertension in India (PO)
  • 01 Sep 2015 No recent reports on development identified - Phase-III for Thrombosis (Prevention) in India (PO)
  • 01 Sep 2015 No recent reports on development identified - Phase-III for Cardiovascular disorders in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top